menu
    • menu
    [{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ HiberCell","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ HiberCell"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"HiberCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Undisclosed"},{"orgOrder":0,"company":"HiberCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Undisclosed"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"HiberCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Undisclosed"},{"orgOrder":0,"company":"HiberCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Undisclosed"},{"orgOrder":0,"company":"HiberCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Undisclosed"},{"orgOrder":0,"company":"HiberCell","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"HiberCell \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Covance"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"}]

    Find Clinical Drug Pipeline Developments & Deals for HC-7366

    Menu

    HC-7366

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Gets FDA Fast Track for HC-7366 in Relapsed AML

                            Details : HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. It is being evaluated for the treatment of r/r AML.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 23, 2024

                            Lead Product(s) : HC-7366,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Doses First Patient in Phase 1b Trial of HC-7366 in AML Treatment

                            Details : HC-7366 is a first-in-human, small molecule activator of the GCN2 kinase, which is being evaluated in combination with venetoclax and azacitidine in AML patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : HC-7366,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Doses First Patient in Merck Collaboration for Advanced ccRCC

                            Details : HC-7366, a selective activator of general control nonderepressible 2 kinases, is under investigation with Welireg for clear cell renal cell carcinoma treatment.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 01, 2024

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MD Anderson Cancer Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MD Anderson Cancer Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : HiberCell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Study of HC-7366 for Acute Myeloid Leukemia

                            Details : HC-7366 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : HiberCell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma

                            Details : HC-7366 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2024

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GC...

                            Details : The collaboration aims to evaluate HiberCell's HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor for the treatment of clear cell renal cell carcinom...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)

                            Details : HC-7366, a first-in-class, first-in-human GCN2 activator. In preclinical studies, HC-7366 was observed to have robust anti-tumor and immunomodulatory activity in a variety of models of solid tumors and hematological malignancies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2023

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for...

                            Details : The posters will present the immunomodulatory mechanisms of HC-7366, a differentiated selective, orally bioavailable activator of GCN2 (general controlled nonderepressible 2). HiberCell is currently conducting Phase 1 clinical trials in solid tumors for ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 02, 2022

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Labcorp Drug Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

                            Details : The first-in-human Phase 1a/b clinical trial, designed to establish maximum tolerated dose, while evaluating safety and tolerability, and to establish recommended Phase 2 dose for HC-7366, selective, orally bioavailable modulator of GNC2 in patients with...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 24, 2022

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Labcorp Drug Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

                            Details : HC-7366 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 16, 2021

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth